Fairvalue-Calculator Fairvalue-Calculator

Haisco Pharmaceutical Group (002653) Fair Value & Analysis

Healthcare · CN · Market cap 54.2B CNY

Price¥49.23
Fair Value¥5.10
Upside-89.6%
Quality95/100
Evidence: High Range ¥3.82 – ¥6.37

Analysis

Haisco Pharmaceutical Group (002653) currently trades at ¥49.23, while our model-based Fair Value estimate is ¥5.10 — implying the stock looks roughly 89.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -82% Samsung Biologics Co (207940) +9%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.